Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma | NEJM

France Nouvelles Nouvelles

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma | NEJM
France Dernières Nouvelles,France Actualités
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse EmoryUniversity nejm

Presented in part at the Annual Meeting of the American Society of Clinical Oncology, June 3–7, 2022., the Quality Assurance Review Center , Imaging and Radiology Oncology Core Rhode Island , the. Support for editing of an earlier version of the manuscript was provided by the Children’s Healthcare of Atlanta and Emory University Pediatric Grant Editing and Manuscript Support Core.provided by the authors are available with the full text of this article at NEJM.org.

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author Affiliations From the Department of Pediatrics, Emory University School of Medicine , and Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta — both in Atlanta; the Department of Biostatistics, Children’s Oncology Group, Statistics and Data Center, University of Florida, Gainesville , and the Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville ; the Institute for Clinical Research and Health Policy Studies and Tufts Cancer Center, Tufts Medical Center, Boston ; the...

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

medical_xpress /  🏆 101. in UK

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of QatarExploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of QatarResearchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.
Lire la suite »

Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5-17 years?Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5-17 years?Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5-17 years? medrxivpreprint COVID19 coronavirus covid vaccination vaccine health
Lire la suite »

Study shows a rise in blood pressure during COVID-19Study shows a rise in blood pressure during COVID-19In a recent study published in the journal Hypertension, researchers examined blood pressure (BP) outcomes in individuals with hypertension during the coronavirus disease 2019 (COVID-19) pandemic.
Lire la suite »

Frontiers | Acute Effect of a Dietary Multi-Ingredient Nootropic as a Cognitive Enhancer in Young Healthy Adults: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover TrialFrontiers | Acute Effect of a Dietary Multi-Ingredient Nootropic as a Cognitive Enhancer in Young Healthy Adults: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover TrialAim: To study the acute effect of a dietary multi-ingredient nootropic on cognitive performance in young healthy adults. We also analyzed the influence of the dietary multi-ingredient nootropic on emotional state, heart rate (HR), and heart rate variability (HRV). Methods: This is a randomized, triple-blinded, placebo-controlled, crossover trial. 26 young healthy adults (50% women; 24.9±3.3 years old) ingested 10g of a dietary multi-ingredient nootropic [Evo-Gamers®; Harrison Sport Nutrition (HSN), Granada, Spain] or placebo (maltodextrin) in a randomized order (clinicaltrials.gov No. NCT04790188). After 30 min of the ingestion, participants performed a battery of cognitive performance tests to measure processing speed, inhibitory control, working memory, cognitive flexibility, creativity, and verbal fluency. Emotional status was assessed through questionnaires and HR and HRV were measured using a heart rate monitor. Results: In comparison with placebo, the acute ingestion of the nootropic showed a significantly better response time in several cognitive tests (i.e., processing speed, inhibitory control, spatial working memory, and cognitive flexibility, all P0.05). Conclusion: An acute ingestion of a dietary multi-ingredient nootropic enhances cognitive performance in comparison with placebo without negatively influencing HR or HRV in young healthy adults.
Lire la suite »

Multi-factor authentication fatigue can blow open securityMulti-factor authentication fatigue can blow open securityOverwhelmed by waves of push notifications, worn-down users inadvertently let the bad guys in
Lire la suite »



Render Time: 2025-04-06 00:17:04